Cytyc pays $160million for breast radiation therapy firm
This article was originally published in Clinica
Executive Summary
Cytyc has agreed to pay $160m in cash for Proxima Therapeutics, a private company with an FDA-cleared post-lumpectomy targeted radiation therapy system for early-stage breast cancer. Proxima also sells a similar system to treat resected brain tumours, which Cytyc hopes to divest because it does not fit into its focus on women's health. Both products involve the use of a balloon catheter to deliver a radiation source directly to the cavity left following the removal of the tumour.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.